Article Text

PDF
Response to: ’Not all drugs (and routes) are same' by Zanwar and Gandhi
  1. Pierre Charles1,2,
  2. Loic Guillevin1
  1. 1Internal Medicine, Referral Center for Rare Systemic and Autoimmune Diseases: Vasculitis and Scleroderma, Cochin Hospital, Paris Descartes University, Paris, France
  2. 2Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France
  1. Correspondence to Professor Loic Guillevin, Department of Internal Medicine, Hôpital Cochin, Paris 75679, France; loic.guillevin{at}orange.fr

Statistics from Altmetric.com

We would like to thank Zanwar and Gandhi1 for their comments regarding our paper.2 We are aware of the long-term results of the European Vasculitis Society (EUVAS) trial: patients treated with daily oral (DO) cyclophosphamide experienced fewer relapses than those given pulse intravenous cyclophosphamide for induction therapy.3 At 18 months, no significant between-group differences were seen and long-term follow-up indicated fewer relapses only for the DO cyclophosphamide group. However, as …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles